1
|
Dingemans A, van Walree N, Schramel F, Youssef-E Soud M, Baltruškevičienė E, Lybaert W, Veldhorst M, Van den Berg C, Kaasa S. High Protein Oral Nutritional Supplements Enable The Majority Of Cancer Patients To Meet ESPEN Protein Recommendations During Systemic Treatment. Clin Nutr ESPEN 2023. [DOI: 10.1016/j.clnesp.2022.09.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/28/2023]
|
2
|
Rasing M, Peters M, Moreno A, Hofman E, Herder J, Welvaart P, Schramel F, Lodeweges J, Lin S, Verhoeff J, Van Rossum P. P1.17-39 Preoperative Prediction of Incomplete Resection in Non-Small Cell Lung Cancer: An Externally Validated Clinical Nomogram. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
3
|
Baas P, Buikhuisen W, Dalesio O, Vincent A, Pavlakis N, Van Klaveren R, Schramel F, Custers F, Schouwink H, Burgers SA. A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7006] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Surmont V, Aerts JGJV, Tan KY, Schramel F, Vernhout R, Hoogsteden HC, van Klaveren RJ. Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study. J Oncol 2009; 2009:457418. [PMID: 19920864 PMCID: PMC2777239 DOI: 10.1155/2009/457418] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/17/2009] [Revised: 07/17/2009] [Accepted: 08/19/2009] [Indexed: 11/25/2022]
Abstract
Background. sequential chemotherapy can maintain dose intensity and preclude cumulative toxicity by increasing drug diversity. Purpose. to investigate the toxicity and efficacy of the sequential regimen of gemcitabine followed by paclitaxel in first line advanced stage non-small cell lung cancer (NSCLC) patients with good performance status (PS). Patients and methods. gemcitabine 1250 mg/m(2) was administered on day 1 and 8 of course 1 and 2; Paclitaxel 150 mg/m(2) on day 1 and 8 of course 3 and 4. Primary endpoint was response rate (RR), secondary endpoints toxicity and time to progression (TTP). Results. Of the 21 patients (median age 56, range 38-80 years; 62% males, 38% females) 10% (2/21) had stage IIIB, 90% (19/21) stage IV, 15% PS 0, 85% PS 1. 20% of patients had a partial response, 30% stable disease, 50% progressive disease. Median TTP was 12 weeks (range 6-52 weeks), median overall survival (OS) 8 months (range 1-27 months), 1-year survival was 33%. One patient had grade 3 hematological toxicity, 2 patients a grade 3 peripheral neuropathy. Conclusions. sequential administration of gemcitabine followed by paclitaxel in first line treatment of advanced NSCLC had a favourable toxicity profile, a median TTP and OS comparable with other sequential trials and might, therefore, be a treatment option for NSCLC patients with high ERCC1 expression.
Collapse
Affiliation(s)
- V. Surmont
- Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands
| | - J. G. J. V. Aerts
- Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands
- Department of Pulmonology, Amphia Hospital, Breda, The Netherlands
| | - K. Y. Tan
- Department of Pulmonology, St. Franciscus Gasthuis, Rotterdam, The Netherlands
| | - F. Schramel
- Department of Pulmonology, St. Antonius, Nieuwegein, The Netherlands
| | - R. Vernhout
- Department of Trials and Statistics, Erasmus MC-Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands
| | - H. C. Hoogsteden
- Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands
| | - R. J. van Klaveren
- Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands
| |
Collapse
|
5
|
Surmont V, van Klaveren RJ, Goor C, Schramel F, Manegold C, Legrand C, Van Schil P, Van Meerbeeck JP. Lessons to learn from EORTC study 08981: A feasibility study of induction chemoradiotherapy followed by surgical resection for stage IIIB non-small cell lung cancer. Lung Cancer 2007; 55:95-9. [PMID: 17069931 DOI: 10.1016/j.lungcan.2006.09.015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2006] [Revised: 09/04/2006] [Accepted: 09/23/2006] [Indexed: 12/29/2022]
Abstract
The present EORTC phase II feasibility study in stage IIIB (T4-N3) NSCLC was conducted to investigate whether an induction regimen with concurrent chemoradiotherapy followed by surgery after restaging by re-mediastinoscopy and/or fluorodeoxyglucose-positron emission tomography (FDG-PET) was feasible in a multicenter setting. Unfortunately, the study closed prematurely because of poor accrual. The combination of more stringent selection criteria, the incorrect prevailing view of Ethical Boards that a tri-modality approach is too toxic, competing studies in the participating centers and the fact that patients with N3 disease could only be enrolled if a re-mediastinoscopy could be performed, underlie the low accrual. Although this study illustrates that the conduct of a tri-modality study across Europe appeared to be difficult at that time, the number of centers with highly qualified and experienced specialists involved in this kind of multi-modality approaches is rapidly increasing. Future initiatives should, therefore, certainly be encouraged. Minimally invasive procedures such as EUS and EBUS should preferably be used for up-front mediastinal staging, mediastinoscopy with or without EUS should preferably be reserved for restaging, and especially right-sided pneumonectomies should be avoided. Though evident, the feasibility to complete this kind of studies within a reasonable time period is still a condition sine qua non.
Collapse
Affiliation(s)
- V Surmont
- Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Groene Hilledijk 301, 3008 AE Rotterdam, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 2006; 17:1698-704. [PMID: 16968876 DOI: 10.1093/annonc/mdl183] [Citation(s) in RCA: 141] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The aim of this prognostic factor analysis was to investigate if a patient's self-reported health-related quality of life (HRQOL) provided independent prognostic information for survival in non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS Pretreatment HRQOL was measured in 391 advanced NSCLC patients using the EORTC QLQ-C30 and the EORTC Lung Cancer module (QLQ-LC13). The Cox proportional hazards regression model was used for both univariate and multivariate analyses of survival. In addition, a bootstrap validation technique was used to assess the stability of the outcomes. RESULTS The final multivariate Cox regression model retained four parameters as independent prognostic factors for survival: male gender with a hazard ratio (HR) = 1.32 (95% CI 1.03-1.69; P = 0.03); performance status (0 to 1 versus 2) with HR = 1.63 (95% CI 1.04-2.54; P = 0.032); patient's self-reported score of pain with HR= 1.11 (95% CI 1.07-1.16; P < 0.001) and dysphagia with HR = 1.12 (95% CI 1.04-1.21; P = 0.003). A 10-point shift worse in the scale measuring pain and dysphagia translated into an 11% and 12% increased in the likelihood of death respectively. A risk group categorization was also developed. CONCLUSION The results suggest that patients' self-reported HRQOL provide independent prognostic information for survival. This finding supports the collection of such data in routine clinical practice.
Collapse
Affiliation(s)
- F Efficace
- European Organisation for Research and Treatment of Cancer (EORTC), EORTC Data Center, Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Smit E, Biesma B, Paul M, van der Tol A, Schramel F, Bolhuis R, Postmus P. P-226 Multicentre phase II trial of accelerated high dose epirubicin and cisplatin followed by surgery in patients with locally advanced non-small cell lung cancer. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80720-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Kramer G, van Meerbeeck J, van Schil P, Uitterhoeve L, Smit E, Schramel F, Biesma B, Tjan-Heijnen V, Legrand C, Splinter T. PD-045 Quality assurance review of thoracic radiotherapy inEORTC 08941: A randomized trial of surgery (S) versus thoracic radiotherapy (RT) in patients (pts) with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy (ICT). Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80378-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Smit E, van Meerbeeck J, Lianes P, Schramel F, Lenz G. An EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)81053-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Pitz C, Brutel de la Riviere A, van Beek F, Schlosser N, Hofman P, Dik H, Kersbergen J, Biesma B, Schramel F. Phase II study of induction chemotherapy in patients with stage IIIB NSCLC. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80292-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
11
|
Van Zandwijk N, Smith E, Kramer G, Schramel F, Gans S, Festen J, Termeer A, Schlosser N, Debruyne C, Curran D, Giaccone G. Gemcitabine and Cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 Non-Small Cell Lung Cancer: A phase II study of the EORTC Lung Cancer Cooperative Group (EORTC 08955). Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80035-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Van Zandwijk N, Smit EF, Kramer GW, Schramel F, Gans S, Festen J, Termeer A, Schlosser NJ, Debruyne C, Curran D, Giaccone G. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000; 18:2658-64. [PMID: 10894864 DOI: 10.1200/jco.2000.18.14.2658] [Citation(s) in RCA: 119] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Our objective was to better define the activity/feasibility of gemcitabine/cisplatin (GC) as induction chemotherapy in patients with stage IIIA N2 non-small-cell lung cancer (NSCLC) followed by surgery or radiotherapy within a large, ongoing comparative study (EORTC 08941). PATIENTS AND METHODS Forty-seven chemotherapy-naive patients with NSCLC, median age of 58 years, stage IIIA N2 disease, World Health Organization performance status of 0 or 1, and the ability to tolerate a pneumonectomy received gemcitabine 1,000 mg/m(2) on days 1, 8, and 15 and cisplatin 100 mg/m(2) on day 2, every 4 weeks. Patients received induction chemotherapy (three cycles) before re-evaluation and randomization to surgery or radiotherapy. RESULTS Grade 3/4 thrombocytopenia, the main hematologic toxicity, occurred in 60% of patients but was not associated with bleeding. Full-dose gemcitabine was given in 48% of the courses. Severe nonhematologic toxicity was uncommon. Two patients with preexisting, autoimmune pulmonary fibrosis had deterioration of pulmonary function after radiotherapy. Thirty-three (70.2%; 95% confidence interval, 55.1% to 82.7%) of the 47 eligible patients had objective responses (three complete responses and 30 partial responses). Mediastinal nodes were tumor-free after induction therapy in 53% of cases. Resections were considered complete in 71% of the patients who underwent thoracotomy after induction therapy. Median survival for all recruited patients (N = 53) was 18.9 months, with an estimated 1-year survival rate of 69%. CONCLUSION In patients with N2 stage IIIA NSCLC, GC is a highly active and well-tolerated induction regimen. GC should be explored in combination with surgery or radiotherapy in stage I and II patients.
Collapse
Affiliation(s)
- N Van Zandwijk
- Netherlands Cancer Institute and Free University, Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
|
14
|
Abstract
Extraluminal tumour compression can be treated with the use of stenting. In 8 patients with end-stage malignant tumours of the tracheobronchial tree, tumor compression of the major airways became apparent after Nd-YAG laser debulking. Dumon-type stents (Endoxane), were inserted under general anaesthesia. There were no complications during and after stent insertion. All stents were well tolerated, with significant symptomatic relief in all patients. This symptomatic relief was considered worthwhile, despite the limited duration of palliation and the pre-terminal stage of the patients. Tumour progression after stent insertion was usually beyond any treatment possibility, except additional laser coagulation. The median survival was 2 months and the longest palliation was 11 months.
Collapse
Affiliation(s)
- G Sutedja
- Department of Pulmonary Medicine, Free University Hospital, Amsterdam, The Netherlands
| | | | | | | |
Collapse
|